January 03rd 2017

Publication news: Safety data reporting the incidence of inflammatory bowel disease for patients with psoriasis treated with ixekizumab are published

Patients with psoriasis are at increased risk of IBD and specific monitoring is required when IL-17A inhibitors are prescribed to patients with IBD. Adjudicated reports of IBD from an integrated clinical trial database of 4209 patients with moderate to severe psoriasis who were treated with the IL-17A inhibitor ixekizumab have been published in the Journal of American Academy of Dermatology.